DENOSUMAB

Brand name:

• Xgeva®

Pharmaceutical company:

AMGEN AUSTRALIA PTY LIMITED

Condition/indication:
(therapeutic use)

• Giant cell tumour of bone; Bone metastases

PBAC Submission type:

New PBS listing (Category 4)

Comment:

--

Public Summary Document:

Not yet available

Related medicines:

--

Submission received for:

March 2025 PBAC meeting

Opportunity for consumer comment:

Open 27/11/2024 and close 29/01/2025 (see PBS Website)

PBAC meeting:

Held on 12/03/2025

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

07/04/2025

Lodgement of required documentation:

15/05/2025

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 19/05/2025

Status:

Finalised

7Government processes:

Commenced on 11/06/2025

8Medicine listed on the PBS:

Has not yet occurred

---